Registry-listed formulations

xingnaojing · mesh:C000594497

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • Xingnaojing injectionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Xingnaojing injectionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Xingnaojing injectionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Xingnaojing injectionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Xingnaojing injectionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
0(0%)

Phase Distribution

Phase 4
4
67%
Not Applicable
1
17%
Phase 1/2
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1/2Combined phases
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Other(6)

Detailed Status

unknown6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 1/21 (16.7%)
Phase 44 (66.7%)
N/A1 (16.7%)

Trials by Status

unknown6100%

Recent Activity

0 active trials
Showing 5 of 6
unknownphase_4

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

NCT05559307
unknownnot_applicable

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04813445
unknownphase_4

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04150835
unknownphase_4

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

NCT02728180
unknownphase_1_2

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

NCT02367248
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05559307Phase 4

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

Unknown
NCT04813445Not Applicable

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Unknown
NCT04150835Phase 4

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Unknown
NCT02728180Phase 4

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Unknown
NCT02367248Phase 1/2

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Unknown
NCT00796380Phase 4

Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases

Unknown

All 6 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
6